DIC; N-[2,5-Difluoro-4-[[2-(1-Methyl-1H-Pyrazol-4-Yl)-4-Pyridinyl]Oxy]Phenyl]-N'-Phenyl-1,1-Cyclopropanedicarboxamide; N-[2,5-Difluoro-4-[[2-(1-Methyl-1H-Pyrazol-4-Yl)-4-Pyridinyl]Oxy]Phenyl]-N'-Phenyl-1,1-Cyclopropanedicarboxamide Dcc-2618; C-Kit-In-1; Dcc-2618, >98%; Dcc-2618?, >98%; Cs-937; Dcc2618; Dcc 2618

Brief Introduction

It has potential anti-tumor activity

Osimertinib Mesylate

CAS:1421373-66-1

Molecular Formula:C28H33N7O2.CH4O3S

Alias

More Information

Mereletinib Mesylate; N-[2-[[2-(Dimethylamino)Ethyl]Methylamino]-4-Methoxy-5-[[4-(1-Methyl-1H-Indol-3-Yl)-2-Pyrimidinyl]Amino]Phenyl]-2-Propenamide Methanesulfonate N-[2-[2-(Dimethylamino)Ethyl-Methylamino]-4-Methoxy-5-[[4-(1-Methylindol-3-yl)Pyrimidin-2-yl]Amino]Phenyl]prop-2-Enamide;Methanesulfonic acid

Brief Introduction

Azd9291 (methanesulfonate), or oxitinib mesylate, is applicable to the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or have disease progression after treatment, and who are confirmed to have positive egfrt790m mutation. Azd9291 (methanesulfonate) has high selectivity. Its IC50 for t790m/l858r mutation and exon 19 deletion EGFR are 11.4nm and 12.9nm respectively, while its IC50 for wild-type EGFR is 494nm. Oxitinib is an irreversible inhibitor of EGFR and can form covalent bonds with molecular targets. Therefore, theoretically, the response lasts longer and the chance of drug resistance is reduced accordingly.

Trastuzumab

CAS:180288-69-1

Molecular Formula:C10H14N6O5

Alias

More Information

Herceptin; Anti HER2, Ig Gamma-1 Chain C Region; Recombinant Humanized anti-HER2 Antibody; Rhumab HER2

Brief Introduction

Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protein. As part of a chemotherapy regimen for the adjuvant treatment of node-positive, HER2/neu-positive cancers.

Erlotinib

CAS:183321-74-6

Molecular Formula:C22H23N3O4

Alias

More Information

Erlotinib Hcl; Erlotinib Hcl Salt; 4-[(3-Ethynylphenyl)Amino]-6,7-Bis(2-Methoxyethoxy)Quinazoline; N-(3-Ethynylphenyl)[6,7-Bis(2-Methoxyethoxy)Quinazolin-4-Yl]Amine; Erlotinib Hydrochloirde; 4-Quinazolinamine, N-(3-Ethynylphenyl)-6,7-Bis(2-Methoxyethoxy)-; Tarceva

Brief Introduction

Erotinib is a receptor tyrosine kinase inhibitor (EGFR antagonist), a molecular targeted therapeutic drug that inhibits phosphorylation reactions by competitively binding to the catalytic site of the intracellular region of the receptor tyrosine kinase with adenosine triphosphate, thereby blocking downstream proliferative signal transduction, inhibiting the activity of tumor cell ligand dependent HER-1/EGFR, and achieving the effect of inhibiting tumor cell proliferation.

Carboplatin

CAS:41575-94-4

Molecular Formula:C6H12N2O4Pt

Alias

More Information

Paraplatin; 1,1-Cyclobutanedicarboxylatediammineplatinum(Ii); 1-Cyclobutanedicarboxylato(2-)-O,O')-Diammine((Sp-4-2)-Platinu; 1-Cyclobutanedicarboxylato)Diammine-(Cis-Platinum(Ii; Diammine(1,1-Cyclobutanedicarboxylato)Platinum(Ii); Carboplatinum; Cis-Diamine(1,1-Cyclobutanedicarboxylato)Platinum

Brief Introduction

The second generation of platinum anticancer drugs have basically the same effect and use as cisplatin. Its activity to some tumors is higher than that of cisplatin. As a radiosensitizer, it is stronger than cisplatin under hypoxia conditions. It is mainly used for ovarian cancer, testicular cancer, small cell lung cancer and head and neck cancer.

1
···
18
19
20
21
22
23
24
25
26

Inquiry (

/ 10

)

Clear All